<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01535014</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-DI-002</org_study_id>
    <nct_id>NCT01535014</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients</brief_title>
  <official_title>Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  To assess safety of Dietressa in the dose of 6 tablets daily within 24 weeks in
           treatment of obese patients.

        -  To assess clinical efficacy of Dietressa in the dose of 6 tablets daily within 24 weeks
           of therapy in reducing body weight in obese patients.

        -  To compare clinical efficacy of two dosage patterns for Dietressa (1 tablet 6 times
           daily and 2 tablets 3 times daily) within 24 weeks in treatment of obese patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In general, patients will be observed during 24 weeks of trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Who Lose at Least 5 Percent of Baseline Body Weight After 24 Weeks of Treatment Weeks of Treatment</measure>
    <time_frame>assessed after 24 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Body Weight Change After 24 Weeks of Treatment</measure>
    <time_frame>assessed after 24 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Relative Change in Body Weight After 24 Weeks of Treatment</measure>
    <time_frame>assessed after 24 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With a Decrease in Body Weight by 5 or More Percent of Baseline Body Weight After 4, 8, 12, 16, 20 and 24 Weeks of Treatment</measure>
    <time_frame>assessed after 4, 8, 12, 16, 20, and 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Relative Weight Change After 4, 8, 12, 16, 20 and 24 Weeks of Treatment</measure>
    <time_frame>assessed after 4, 8, 12, 16, 20 and 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Hip Ratio After 4, 12 and 24 Weeks of Treatment</measure>
    <time_frame>assessed after 4,12 and 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Quality of Life According to the Data of SF-36 Health Status Survey Questionnaire (SF-36) After 4, 12 and 24 Weeks of Treatment</measure>
    <time_frame>baseline, 4, 12 and 24 weeks</time_frame>
    <description>36 items of the questionnaire are grouped into eight subscales. The subscales are grouped in two scales: the &quot;physical component of health&quot; and &quot;mental health component&quot;. The scores of each scale range between 0 and 100: the higher the score, the better the quality of life and the better the patient's health.
The instruction is not given completely because of the large volume. For more information, see: Ware J.E., Snow K.K., Kosinski M., Gandek B. SF-36 Health Survey. Manual and interpretation guide //The Health Institute, New England Medical Center. Boston, Mass.-1993. In this instruction is explained how eight subscales are combined to compute a total score.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">493</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Dietressa (2 tablets 3 times daily) for 24 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Dietressa (2 tablets 3 times daily) for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dietressa (1 tablet 6 times daily) for 24 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Dietressa (1 tablet 6 times daily) for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (2 tablets 3 times daily)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Placebo (2 tablets 3 times daily) for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (1 tablet 6 times daily)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Placebo (1 tablet 6 times daily) for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dietressa</intervention_name>
    <description>Comparison of different dosages (frequency) of drug</description>
    <arm_group_label>Dietressa (1 tablet 6 times daily) for 24 weeks</arm_group_label>
    <arm_group_label>Dietressa (2 tablets 3 times daily) for 24 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo either (2 tablets 3 times daily) or
(1 tablet 6 times daily)</description>
    <arm_group_label>Placebo (1 tablet 6 times daily)</arm_group_label>
    <arm_group_label>Placebo (2 tablets 3 times daily)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Outpatient subjects with BMI 30,0-34,9 kg/m2.

          2. Male or female subjects aged 18 to 65 inclusive.

          3. Use of and compliance with contraception methods by patients of reproductive age, of
             both sexes.

          4. Presence of the patient's information sheet (informed consent form) for participation
             in the clinical trial.

        Exclusion Criteria:

          1. Symptomatic (secondary) obesity:

               -  with established genetic defect (including as a part of known genetic syndromes
                  affecting multiple organs): Prader-Willi syndrome, Alstrom's syndrome,
                  Laurence-Moon-Biedl syndrome, Dercum's syndrome etc.

               -  cerebral (adiposogenital dystrophy, Babinski-Frohlich syndrome): brain tumors;
                  dissemination of systemic lesions, infectious diseases; against mental diseases.

               -  endocrine: hypothyroid; hypoovarial; pituitary-hypothalamic disorders;
                  adrenopathy.

               -  iatrogenic (caused by drug administration, namely, insulin, glucocorticosteroids,
                  neuroleptics etc.).

          2. Compliance with a diet prescribed and monitored by the doctor to reduce body weight
             within 6 months before enrollment.

          3. Participation in the lifestyle modification program within 6 months before enrollment.

          4. Patients who quit smoking within 6 months before enrollment, or intending to quit
             smoking during the period of participation in the trial, as well as intending to begin
             smoking during the trial.

          5. Uncontrolled arterial hypertension (patients with 1-3 degree AH, receiving no adequate
             antihypertensive therapy).

          6. Type 1 and 2 diabetes mellitus.

          7. Edema syndrome with various etiology (chronic cardiac failure, nephrotic syndrome,
             hepatic cirrhosis).

          8. Circulatory failure, II–ê degree and above.

          9. Decompensated cardiovascular disease, liver, kidney or gastrointestinal tract disease,
             metabolic, respiratory, endocrine, hematologic disease, peripheral vessel disease or
             another medical state. Oncological disease.

         10. Diseases and states, which, in the investigator's opinion, may prevent the patient
             from participating in the trial.

         11. Past history of bulimia / non-drug abepithymia.

         12. Past history of any bariatric surgeries.

         13. Lipoplasty underwent less then 1 year prior to screening visit, or cavitary surgery
             less then 6 months prior to screening visit.

         14. Surgeries scheduled within 6 months.

         15. Allergy to/intolerance of any of the drug components used during treatment.

         16. Malabsorption syndrome, including congenial or acquired lactase or another
             disaccharidase insufficiency.

         17. Administration of drugs specified as &quot;Prohibited concomitant therapy&quot;, within 6 months
             before enrollment.

         18. Pregnancy, breast-feeding, unwillingness to comply with contraception methods during
             the trial and within 30 days after completion of participation in the trial.

         19. Drug and alcohol consumption (over 2 alc. units daily), mental diseases. Legal
             incapacity or limited legal capacity.

        21. Patients, who, in the investigator's opinion, will fail to observe the requirements
        during the trial or adhere to the studied drug administration procedure.

        22. Participation in other clinical trials within 3 months before enrolment in this trial.

        23. Presence of other factors, complicating the patient's participation in the trial (e.g.,
        planned lengthy business and other trips). 24. A patient is a part of the center's research
        staff, taking a direct part in the trial, or an immediate family member of the
        investigator. Immediate family members are defined as spouses, parents, children or
        siblings, regardless of whether full blood or adopted.

        25. The patient is employed with Scientific Production Firm Materia Medica Holding LLC,
        i.e. is the company's employee, part-time employee under contract, or appointed official in
        charge of the trial, or their immediate family.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The State Educational institution of High Professional Training Kuban State Medical University of Ministry of Health Care and Social Development of the Russian Federation, Department of Clinical Pharmacology</name>
      <address>
        <city>Krasnodar</city>
        <zip>350063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Educational institution of High Professional Training I.M. Sechenov First Moscow State Medical University of Ministry of Health Care and Social Development of the Russian Federation, Endocrinology Faculty</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Budget Health Care institution of Moscow the City Clinical Hospital No. 11 of the Administration of Health Care of Moscow City</name>
      <address>
        <city>Moscow</city>
        <zip>127018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Medical and Preventive institution &quot;City Clinical Hospital No.10&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Budget Health Care institution of Nizhegorodskyi Region &quot;Nizhegorodskaya Regional Clinical Hospital n.a. N.A.Semashko&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Educational institution of High Professional Training &quot;Rostov State Medical University&quot; of Ministry of Health Care and Social Development of the Russian Federation, Department of Endocrinology</name>
      <address>
        <city>Rostov na Donu</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Health Care institution &quot;Municipal Hospital No.6&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191482</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Health Care institution &quot;Municipal Hospital No.77 of Nevsky District&quot;, The City Diabetes Center</name>
      <address>
        <city>St. Petersburg</city>
        <zip>192177</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Federal State Health Care institution L.G. Sokolov Memorial Hospital No. 122 of the FMBA (Federal Medical and Biological Agency).</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Educational institution of High Professional Training &quot;St. Petersburg State Medical University n.a. I.P. Pavlov of the Federal Agency for Health Care and Social Development&quot;, Therapy Faculty Board</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg state Health Care institution &quot;Saint Venerable Martyr Elizaveta Municipal Hospital&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Health Care institution &quot;Consultative and Diagnostic Center No. 85&quot;, Diabetes Center</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198260</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Educational institution of High Professional Training &quot;St. Petersburg State Medical University n.a. I.P. Pavlov of the Federal Agency for Health Care and Social Development&quot;, Faculty Surgery Board</name>
      <address>
        <city>St.Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Educational institution of High Professional Training &quot;Bashkirsky State Medical University&quot; of the Federal Agency for Health Care and Social Development, Department of Endocrinology</name>
      <address>
        <city>Ufa</city>
        <zip>450000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Educational institution of High Professional Training &quot;Volgograd State Medical University&quot; of Ministry of Health Care and Social Development of the Russian Federation</name>
      <address>
        <city>Volgograd</city>
        <zip>400131</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Health Care institution &quot;Voronezh Regional Clinical Consultative &amp; Diagnostic Center&quot;</name>
      <address>
        <city>Voronezh</city>
        <zip>394018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Health Care institution of Yaroslavl Region the Clinical Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 14, 2012</study_first_submitted>
  <study_first_submitted_qc>February 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2012</study_first_posted>
  <results_first_submitted>October 30, 2017</results_first_submitted>
  <results_first_submitted_qc>October 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 18, 2018</results_first_posted>
  <last_update_submitted>November 1, 2018</last_update_submitted>
  <last_update_submitted_qc>November 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dietressa 1</title>
          <description>Dietressa: 1 tablet 6 times daily</description>
        </group>
        <group group_id="P2">
          <title>Dietressa 2</title>
          <description>Dietressa: 2 tablets 3 times daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo 3</title>
          <description>Placebo: 1 tablet 6 times daily</description>
        </group>
        <group group_id="P4">
          <title>Placebo 4</title>
          <description>Placebo: 2 tablets 3 times daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="210"/>
                <participants group_id="P2" count="200"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
                <participants group_id="P2" count="194"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dietressa 1</title>
          <description>Dietressa: 1 tablet 6 times daily</description>
        </group>
        <group group_id="B2">
          <title>Dietressa 2</title>
          <description>Dietressa: 2 tablets 3 times daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo 3</title>
          <description>Placebo: 1 tablet 6 times daily</description>
        </group>
        <group group_id="B4">
          <title>Placebo 4</title>
          <description>Placebo: 2 tablets 3 times daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="208"/>
            <count group_id="B2" value="194"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="33"/>
            <count group_id="B5" value="484"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.2" spread="12.1"/>
                    <measurement group_id="B2" value="42.4" spread="12.1"/>
                    <measurement group_id="B3" value="41.4" spread="10.3"/>
                    <measurement group_id="B4" value="42.8" spread="11.3"/>
                    <measurement group_id="B5" value="41.9" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="422"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.4" spread="8.3"/>
                    <measurement group_id="B2" value="165.1" spread="7.9"/>
                    <measurement group_id="B3" value="164.4" spread="6.7"/>
                    <measurement group_id="B4" value="164.9" spread="7.8"/>
                    <measurement group_id="B5" value="165.6" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.1" spread="10.6"/>
                    <measurement group_id="B2" value="87.5" spread="9.5"/>
                    <measurement group_id="B3" value="87.1" spread="7.7"/>
                    <measurement group_id="B4" value="86.1" spread="9.8"/>
                    <measurement group_id="B5" value="88.1" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kilogram/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="1.4"/>
                    <measurement group_id="B2" value="32.0" spread="1.5"/>
                    <measurement group_id="B3" value="32.2" spread="1.5"/>
                    <measurement group_id="B4" value="31.6" spread="1.3"/>
                    <measurement group_id="B5" value="32.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Lose at Least 5 Percent of Baseline Body Weight After 24 Weeks of Treatment Weeks of Treatment</title>
        <time_frame>assessed after 24 weeks of treatment</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Dietressa 1</title>
            <description>Dietressa: 1 tablet 6 times daily</description>
          </group>
          <group group_id="O2">
            <title>Dietressa 2</title>
            <description>Dietressa: 2 tablets 3 times daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo 3</title>
            <description>Placebo: 1 tablet 6 times daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo 4</title>
            <description>Placebo: 2 tablets 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Lose at Least 5 Percent of Baseline Body Weight After 24 Weeks of Treatment Weeks of Treatment</title>
          <population>Intention to treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Body Weight Change After 24 Weeks of Treatment</title>
        <time_frame>assessed after 24 weeks of treatment</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Dietressa 1</title>
            <description>Dietressa: 1 tablet 6 times daily</description>
          </group>
          <group group_id="O2">
            <title>Dietressa 2</title>
            <description>Dietressa: 2 tablets 3 times daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo 3</title>
            <description>Placebo: 1 tablet 6 times daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo 4</title>
            <description>Placebo: 2 tablets 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Average Body Weight Change After 24 Weeks of Treatment</title>
          <population>Intention to treat</population>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="4.2"/>
                    <measurement group_id="O2" value="-4.4" spread="4.4"/>
                    <measurement group_id="O3" value="-3.0" spread="3.5"/>
                    <measurement group_id="O4" value="-2.9" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Relative Change in Body Weight After 24 Weeks of Treatment</title>
        <time_frame>assessed after 24 weeks of treatment</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Dietressa 1</title>
            <description>Dietressa: 1 tablet 6 times daily</description>
          </group>
          <group group_id="O2">
            <title>Dietressa 2</title>
            <description>Dietressa: 2 tablets 3 times daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo 3</title>
            <description>Placebo: 1 tablet 6 times daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo 4</title>
            <description>Placebo: 2 tablets 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Average Relative Change in Body Weight After 24 Weeks of Treatment</title>
          <population>Intention to treat</population>
          <units>percentage of body weight</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="4.7"/>
                    <measurement group_id="O2" value="-4.9" spread="4.9"/>
                    <measurement group_id="O3" value="-3.4" spread="4.2"/>
                    <measurement group_id="O4" value="-3.4" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With a Decrease in Body Weight by 5 or More Percent of Baseline Body Weight After 4, 8, 12, 16, 20 and 24 Weeks of Treatment</title>
        <time_frame>assessed after 4, 8, 12, 16, 20, and 24 weeks of treatment</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Dietressa 1</title>
            <description>Dietressa: 1 tablet 6 times daily</description>
          </group>
          <group group_id="O2">
            <title>Dietressa 2</title>
            <description>Dietressa: 2 tablets 3 times daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo 3</title>
            <description>Placebo: 1 tablet 6 times daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo 4</title>
            <description>Placebo: 2 tablets 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With a Decrease in Body Weight by 5 or More Percent of Baseline Body Weight After 4, 8, 12, 16, 20 and 24 Weeks of Treatment</title>
          <population>Intention to treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>For week 12, 16, 20, 24</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>For week 16, 20, 24</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Relative Weight Change After 4, 8, 12, 16, 20 and 24 Weeks of Treatment</title>
        <time_frame>assessed after 4, 8, 12, 16, 20 and 24 weeks of treatment</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Dietressa 1</title>
            <description>Dietressa: 1 tablet 6 times daily</description>
          </group>
          <group group_id="O2">
            <title>Dietressa 2</title>
            <description>Dietressa: 2 tablets 3 times daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo 3</title>
            <description>Placebo: 1 tablet 6 times daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo 4</title>
            <description>Placebo: 2 tablets 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Average Relative Weight Change After 4, 8, 12, 16, 20 and 24 Weeks of Treatment</title>
          <population>Intention to treat</population>
          <units>percentage of body weight</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="1.8"/>
                    <measurement group_id="O2" value="-1.4" spread="2.1"/>
                    <measurement group_id="O3" value="-0.8" spread="2.1"/>
                    <measurement group_id="O4" value="-0.8" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="2.6"/>
                    <measurement group_id="O2" value="-2.5" spread="2.7"/>
                    <measurement group_id="O3" value="-1.3" spread="3.8"/>
                    <measurement group_id="O4" value="-1.5" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="3.1"/>
                    <measurement group_id="O2" value="-3.3" spread="3.4"/>
                    <measurement group_id="O3" value="-2.1" spread="3.2"/>
                    <measurement group_id="O4" value="-2.2" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="3.7"/>
                    <measurement group_id="O2" value="-4.0" spread="3.9"/>
                    <measurement group_id="O3" value="-2.8" spread="3.7"/>
                    <measurement group_id="O4" value="-2.6" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="4.1"/>
                    <measurement group_id="O2" value="-4.5" spread="4.4"/>
                    <measurement group_id="O3" value="-3.1" spread="4.0"/>
                    <measurement group_id="O4" value="-2.8" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="4.7"/>
                    <measurement group_id="O2" value="-4.9" spread="4.9"/>
                    <measurement group_id="O3" value="-3.4" spread="4.2"/>
                    <measurement group_id="O4" value="-3.4" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Hip Ratio After 4, 12 and 24 Weeks of Treatment</title>
        <time_frame>assessed after 4,12 and 24 weeks of treatment</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Dietressa 1</title>
            <description>Dietressa: 1 tablet 6 times daily</description>
          </group>
          <group group_id="O2">
            <title>Dietressa 2</title>
            <description>Dietressa: 2 tablets 3 times daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo 3</title>
            <description>Placebo: 1 tablet 6 times daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo 4</title>
            <description>Placebo: 2 tablets 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Hip Ratio After 4, 12 and 24 Weeks of Treatment</title>
          <population>Intention to treat</population>
          <units>waist hip ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.08"/>
                    <measurement group_id="O2" value="0.89" spread="0.09"/>
                    <measurement group_id="O3" value="0.89" spread="0.07"/>
                    <measurement group_id="O4" value="0.86" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.08"/>
                    <measurement group_id="O2" value="0.89" spread="0.09"/>
                    <measurement group_id="O3" value="0.88" spread="0.08"/>
                    <measurement group_id="O4" value="0.85" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.08"/>
                    <measurement group_id="O2" value="0.88" spread="0.09"/>
                    <measurement group_id="O3" value="0.87" spread="0.08"/>
                    <measurement group_id="O4" value="0.85" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="0.08"/>
                    <measurement group_id="O2" value="0.88" spread="0.09"/>
                    <measurement group_id="O3" value="0.87" spread="0.08"/>
                    <measurement group_id="O4" value="0.85" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Quality of Life According to the Data of SF-36 Health Status Survey Questionnaire (SF-36) After 4, 12 and 24 Weeks of Treatment</title>
        <description>36 items of the questionnaire are grouped into eight subscales. The subscales are grouped in two scales: the &quot;physical component of health&quot; and &quot;mental health component&quot;. The scores of each scale range between 0 and 100: the higher the score, the better the quality of life and the better the patient's health.
The instruction is not given completely because of the large volume. For more information, see: Ware J.E., Snow K.K., Kosinski M., Gandek B. SF-36 Health Survey. Manual and interpretation guide //The Health Institute, New England Medical Center. Boston, Mass.-1993. In this instruction is explained how eight subscales are combined to compute a total score.</description>
        <time_frame>baseline, 4, 12 and 24 weeks</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Dietressa 1</title>
            <description>Dietressa: 1 tablet 6 times daily</description>
          </group>
          <group group_id="O2">
            <title>Dietressa 2</title>
            <description>Dietressa: 2 tablets 3 times daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo 3</title>
            <description>Placebo: 1 tablet 6 times daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo 4</title>
            <description>Placebo: 2 tablets 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Quality of Life According to the Data of SF-36 Health Status Survey Questionnaire (SF-36) After 4, 12 and 24 Weeks of Treatment</title>
          <description>36 items of the questionnaire are grouped into eight subscales. The subscales are grouped in two scales: the &quot;physical component of health&quot; and &quot;mental health component&quot;. The scores of each scale range between 0 and 100: the higher the score, the better the quality of life and the better the patient's health.
The instruction is not given completely because of the large volume. For more information, see: Ware J.E., Snow K.K., Kosinski M., Gandek B. SF-36 Health Survey. Manual and interpretation guide //The Health Institute, New England Medical Center. Boston, Mass.-1993. In this instruction is explained how eight subscales are combined to compute a total score.</description>
          <population>Intention to treat</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 week (mental)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7" spread="9.5"/>
                    <measurement group_id="O2" value="43.4" spread="10.4"/>
                    <measurement group_id="O3" value="44.3" spread="9.5"/>
                    <measurement group_id="O4" value="47.5" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks (mental)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" spread="9.3"/>
                    <measurement group_id="O2" value="46.1" spread="9.8"/>
                    <measurement group_id="O3" value="49.0" spread="9.1"/>
                    <measurement group_id="O4" value="49.5" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks (mental)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" spread="9.3"/>
                    <measurement group_id="O2" value="46.6" spread="10.2"/>
                    <measurement group_id="O3" value="49.3" spread="6.3"/>
                    <measurement group_id="O4" value="49.0" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks (mental)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" spread="8.7"/>
                    <measurement group_id="O2" value="47.5" spread="9.2"/>
                    <measurement group_id="O3" value="50.6" spread="7.0"/>
                    <measurement group_id="O4" value="50.0" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 week (physical)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="7.9"/>
                    <measurement group_id="O2" value="49.5" spread="7.3"/>
                    <measurement group_id="O3" value="49.5" spread="7.3"/>
                    <measurement group_id="O4" value="50.7" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks (physical)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2" spread="7.1"/>
                    <measurement group_id="O2" value="50.1" spread="6.8"/>
                    <measurement group_id="O3" value="51.0" spread="6.8"/>
                    <measurement group_id="O4" value="51.5" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks (physical)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" spread="6.4"/>
                    <measurement group_id="O2" value="50.8" spread="7.2"/>
                    <measurement group_id="O3" value="51.3" spread="5.9"/>
                    <measurement group_id="O4" value="50.7" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks (physical)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" spread="6.5"/>
                    <measurement group_id="O2" value="51.3" spread="6.9"/>
                    <measurement group_id="O3" value="51.7" spread="6.2"/>
                    <measurement group_id="O4" value="52.3" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>SF-36 Mental Health Domain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>SF-36 Mental Health Domain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>SF-36 Physical Health Domain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>SF-36 Physical Health Domain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse/Serious adverse events were registered during 12 months of therapy and 30 days after the end of the research</time_frame>
      <desc>Adverse/Serious adverse events were registered in patients of the Full Analysis Set (n=493, Safety Population)</desc>
      <group_list>
        <group group_id="E1">
          <title>Dietressa 1+2</title>
          <description>Dietressa 1: 1 tablet 6 times daily; Dietressa 2: 2 tablets 3 times daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo 3+4</title>
          <description>Placebo 3: 1 tablet 6 times daily; Placebo 4: 2 tablets 3 times daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc sequestration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vertebral osteochondrosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>iron-deficient anemia</sub_title>
                <description>mild disease</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>–°oronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Complaints about palpitations, sweating</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis. Subclinical hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epigastric pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dentalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Epigastric burning</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>nausea after taking the drug before eating</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Heaviness in the right hypochondrium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Enzymatic insufficiency</sub_title>
                <description>ulcerative disease</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>–°hronic gastritis</sub_title>
                <description>acute exacerbation of a chronic disease</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Frequent stool up to 3 times a day</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>exacerbation of chronic pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pastosity of the shins</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Acroedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Increase of ability to work</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Thirst perception</sub_title>
                <description>drinks more fluids</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory viral infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Acute respiratory disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Acute respiratory disease</sub_title>
                <description>with tracheobronchitis</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Acute bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Acute laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Acute rhinopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Acute pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligamentous injury</sub_title>
                <description>1st metacarpophalangeal right hand joint</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increase in arterial pressure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>LDL increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>C-reactive protein increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Glucose level increase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Total cholesterol increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>HDL increase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Erythrocyte sedimentation rate increase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lymphocytosis level increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>ALT increase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Basophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Erytrocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Monocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Suppressing appetite</sub_title>
                <description>Suppressing appetite, feeling of saturation, has become overeat</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <description>Feeling appetite suppressed, decreased feelings of hunger</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Suppressing appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia fasting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Glucose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypercholesteremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <description>for sweet food</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Periodic strong desire to eat something</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dorsopathy of a spine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>gonarthrosis</sub_title>
                <description>left</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Stiffness in hands</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lumbar osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Right shoulder joint arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Left hip joint arthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Unpleasant sweetish taste in a mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vertebral radiculopathy with moderate musculo-tonic and pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Clinical anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Subclinical anxiety</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Increased anxiety on a scale HADS</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Mood changes: a tendency towards depression, aggressiveness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Subclinical depression</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Clinical depression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Increased depression on a scale HADS</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Exaggeratedly mood, unreasonable euphoria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Unpleasant smell of urine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hoarseness and throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash (allergic reaction)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Increased brittleness of nails</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Atopic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensic crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Putilovskiy, MD, PhD, Clinical Research and Medical Information Director</name_or_title>
      <organization>Materia Medica Holding</organization>
      <phone>+74952761571 ext 302</phone>
      <email>PutilovskiyMA@materiamedica.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

